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C A N C E R
A novel proangiogenic B cell subset is increased 
in cancer and chronic inflammation
Willem van de Veen1,2, Anna Globinska1, Kirstin Jansen1,2, Alex Straumann3, Terufumi Kubo4, 
Daniëlle Verschoor1, Oliver F. Wirz1, Francesc Castro-Giner1,5, Ge Tan1,5, Beate Rückert1, 
Urs Ochsner1, Marietta Herrmann6,7, Barbara Stanić1, Marloes van Splunter1, Daan Huntjens1, 
Alexandra Wallimann1,6, Rodney J. Fonseca Guevara1, Hergen Spits8,9, Desislava Ignatova10, 
Yun-Tsan Chang10, Christina Fassnacht10, Emmanuella Guenova10,11, Lukas Flatz12,13,14,  
Cezmi A. Akdis1,2, Mübeccel Akdis1*
B cells contribute to immune responses through the production of immunoglobulins, antigen presentation, 
and cytokine production. Several B cell subsets with distinct functions and polarized cytokine profiles have been 
reported. In this study, we used transcriptomics analysis of immortalized B cell clones to identify an IgG4+ B cell 
subset with a unique function. These B cells are characterized by simultaneous expression of proangiogenic 
cytokines including VEGF, CYR61, ADM, FGF2, PDGFA, and MDK. Consequently, supernatants from these clones 
efficiently promote endothelial cell tube formation. We identified CD49b and CD73 as surface markers identifying 
proangiogenic B cells. Circulating CD49b+CD73+ B cells showed significantly increased frequency in patients with 
melanoma and eosinophilic esophagitis (EoE), two diseases associated with angiogenesis. In addition, tissue- 
infiltrating IgG4+CD49b+CD73+ B cells expressing proangiogenic cytokines were detected in patients with EoE 
and melanoma. Our results demonstrate a previously unidentified proangiogenic B cell subset characterized by 
expression of CD49b, CD73, and proangiogenic cytokines.
INTRODUCTION
The function of B cells has long been thought to be limited to the 
generation of immunoglobulin-producing plasma cells. However, 
B cells can exert a more diverse range of immune effector and reg-
ulatory functions. Distinct functional B cell subsets have been 
identified on the basis of their cytokine production profiles. Immuno-
suppressive B regulatory (reg) cells (1) and other potential B cell sub-
sets, such as B effector 1 (Be1) and Be2 cells, as well as interleukin-17 
(IL-17)–producing B cells, have been reported (2, 3). B cells can 
secrete a wide range of cytokines and accumulate in chronic inflam-
matory areas and around tumor cells. Their interaction with tissue 
cells and tumor cells and their contribution to tissue remodeling 
remain largely open questions.
Angiogenesis is an essential physiological process that occurs 
during embryogenesis, normal tissue development, and repair after 
injury. Through a controlled series of events, angiogenesis allows new 
vessels to grow from preexisting vessels to meet the physiological 
needs of tissues (4). Angiogenesis also plays a role in tumor growth 
(5) and is involved in tissue remodeling in chronic inflammatory 
conditions such as asthma and eosinophilic esophagitis (EoE) (6).
A wide range of secreted molecules promotes this process through 
direct interaction with vascular endothelial cells. These include vas-
cular endothelial growth factors (VEGFs), fibroblast growth factors 
(FGFs), platelet-derived growth factors (PDGFs), hepatocyte growth 
factors, axon guidance factors, and angiopoietins (7). Other factors, 
including cysteine-rich angiogenic inducer 61 (CYR61) (8), andro-
medullin (ADM) (9), and midkine (MDK) (10), have also been 
reported to promote angiogenesis. Free adenosine also promotes 
angiogenesis both through its direct mitogenic effects on endothelial 
cells and through induction of proangiogenic factors such as VEGF, 
IL-8, and FGF from vascular and immune cells (11). Extracellular 
adenosine 5′-triphosphate (ATP) levels are significantly elevated in 
inflamed and hypoxic tissues. This extracellular ATP can be rapidly 
hydrolyzed by ectonucleotidases. CD39 is an ectonucleoside tri-
phosphate diphosphohydrolase and is the rate-limiting enzyme in 
the conversion of ATP and adenosine 5′-diphosphate into adenosine 
5′-monophosphate (AMP) (12). AMP is then converted to adenosine 
by ecto-5′-nucleotidase (NT5E), also known as CD73. CD39 is ex-
pressed on most peripheral (>90%) B cells and monocytes and can 
be expressed on a subset of CD4+ T cells, cytotoxic T cells, and natural 
killer (NK) cells (12) while CD73 is expressed by 75% of the B cells 
and a subset of CD8+ T cells, CD4+ T cells, and NK cells (12).
CD49b, also known as integrin subunit alpha 2 (ITGA2), is ex-
pressed as a part of the 21 integrin heterodimer on platelets, NK 
cells, T cells, and fibroblasts. 21 functions as a collagen receptor. 
The 1 subunit (CD29) is expressed on most of the hematopoietic 
and nonhematopoietic cells. CD49b and LAG-3 coexpression has 
been reported as a signature of type 1 regulatory (Tr1) T cells (13).
Immunoglobulin G4 (IgG4) can be regarded as an anti- 
inflammatory immunoglobulin isotype because of its low affinity 
for binding to Fc receptors, its inability to fix complement, and 
its functional monovalency, which results from its rearrangement 
of immunoglobulin heavy chains by a mechanism called Fab arm 
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exchange (14, 15). No murine antibody isotype exists that shares 
these characteristics with human IgG4; therefore, mouse models are 
not suitable to study this immunological mechanisms associated with 
IgG4. IgG4 appears to play a role in the induction and maintenance 
of immune tolerance to allergens by blocking allergen-specific IgE, 
and allergen-specific IgG4 antibodies are significantly increased 
during the course of allergen-specific immunotherapy and in high-
dose allergen–exposed individuals, such as beekeepers and cat 
owners (16, 17).
Besides its potential role in immune tolerance to allergens, IgG4 
has also been associated with pathological conditions. EoE, melanoma, 
and IgG4-related diseases are associated with structural tissue re-
modeling including angiogenesis. Enhanced IgG4 responses have 
been reported in patients with EoE where high amounts of IgG4 
antibodies against food allergens associated with EoE were found. 
These patients did not show elevated specific IgE levels (18). More-
over, tissue IgG4 levels were later found to correlate with other 
disease parameters including esophageal eosinophil counts, as well 
as IL-4, IL-10, and IL-13 expression (19). Increased angiogenesis has 
been reported in the esophageal mucosa of patients with pediatric 
EoE (20). IgG4-expressing tissue-infiltrating B cells were found near 
tumors in patients with melanoma, and these tumor-associated 
B cells were polarized to produce IgG4. Both tumor-specific and 
nonspecific IgG4 antibodies blocked IgG1-mediated tumoricidal 
functions. Moreover, serum IgG4 was inversely correlated with 
patient survival and disease-free survival (21, 22).
In this study, we identify B cells that express IgG4 and produce 
proangiogenic cytokines and have the capacity to promote angio-
genesis. We further show that these cells are characterized by the 
expression of CD49b and CD73. Cells with this phenotype are elevated 
in circulation of patients with EoE and melanoma and are present 
in affected tissues. Thus, our findings reveal a previously unidentified 
proangiogenic B cell subset that is associated with tissue remod-
eling in chronic inflammatory conditions and tumor angiogenesis.
RESULTS
A subset of B cells promotes angiogenesis
Using a previously described method of B cell immortalization (23), 
we generated a set of 27 memory B cell clones, of which 10 were 
IgG4+ and 17 were IgG1+ from eight individuals. The generation 
and characteristics of the clones are shown in fig. S1 and table S1, 
respectively. To determine the cytokine expression profile of each 
individual clone, B cell clones were stimulated for 4 hours with 
anti–B cell receptor (BCR), after which RNA expression was analyzed 
using next-generation sequencing. B cell clones were clustered on 
the basis of their expression of the top 100 most variably expressed 
genes encoding secreted immunomodulatory proteins (fig. S2). 
This approach resulted in the identification of a cluster of B cells 
showing marked up-regulation of cytokines with known angiogenesis- 
promoting characteristics. All of the B cells that comprised this 
“proangiogenic” cluster were IgG4+ (Fig. 1A). Differential expression 
analysis [false discovery rate (FDR) < 0.01, log2 fold change > 0.5] 
between the proangiogenic cluster and the other nonangiogenic 
B cell clones showed a significant up-regulation of genes encoding 
cytokines that are known to promote angiogenesis, tissue remodel-
ing, and wound healing such as VEGFA, PDGFA, CYR61, bone 
morphogenic protein 2 (BMP2), slit homolog 2 (SLIT2), ADM2, FGF2, 
nephroblastoma overexpressed (NOV), secreted phosphoprotein 1 
(SPP1), PDGFC, hepatoma-derived growth factor-related protein 3 
(HDGFRP3), tumor necrosis factor receptor superfamily member 
11B (TNFRSF11B), CXCL8 (encoding IL-8), MDK, and others 
(Fig. 1, A and B). Several genes with pleiotropic or unknown effects 
on angiogenesis, including IL-36 receptor antagonist (IL36RN), 
IL36B, IL-1 receptor antagonist (IL1RN), VGF, and transforming 
growth factor 2 (TGFB2), were up-regulated as well. Expression of 
IL10, IL16, semaphorin-4A (SEMA4A), C-C motif chemokine 22 
(CCL22), and TNF-related apoptosis–inducing ligand (TNFSF10) 
was down-regulated in proangiogenic clones. While the effects of 
IL-10, CCL22, and IL-16 on angiogenesis remain unclear, as both 
pro- and antiangiogenic effects have been reported, TNFSF10 and 
SEMA4 have been shown to negatively regulate angiogenesis (24, 25). 
The cytokine expression profile of this proangiogenic cluster was 
remarkably stable, as indicated by real-time polymerase chain re-
action (PCR) analysis performed after 3 weeks of culture with 
CD40L and IL-21 followed by 4 hours of stimulation with anti-BCR 
(Fig. 1, B and C). Expression of the proangiogenic cytokines VEGF-A, 
CYR61, FGF2, and IL-8 could also be induced in primary peripheral 
B cells (fig. S3). The culture conditions used for the expansion of 
immortalized B cell clones (CD40L + IL-21) in combination with 
anti-BCR stimulation most effectively induced the production of 
these cytokines in primary B cells (fig. S3).
To assess the functional capacity of proangiogenic B cell clones, 
we tested their potential to promote tube formation of human 
umbilical vein endothelial cells (HUVECs) (26). Supernatants col-
lected from anti-BCR–stimulated proangiogenic B cell clones induced 
an increase of the total tube length (average increase, 1.9-fold over 
control) and number of junctions (average increase, 4.9-fold over 
control) in the tube formation assay (Fig. 1, D and E, and fig. S4), 
demonstrating their functional capacity to promote angiogenesis.
Proangiogenic B cells are characterized by expression 
of CD49b and CD73
To determine surface markers associated with proangiogenic B cells, 
we looked at differentially expressed genes encoding cell surface 
proteins. This resulted in the identification of 20 surface markers 
that were significantly differentially expressed (FDR < 0.01, log2 
fold change > 0.5) between pro- and nonangiogenic B cell clones 
(Fig. 2A). Of these genes, PVRL2 (encoding CD112), NT5E (encoding 
CD73), CD276, ITGA2 (encoding CD49b), IL1R1 (encoding CD121a), 
and CDH2 (encoding CD325) showed the most uniform differential 
expression profile with high expression on proangiogenic clones and 
low expression on nonangiogenic clones. Consistently up-regulated 
surface expression of CD49b and CD73 was observed on proangiogenic 
B cell clones by flow cytometry (Fig. 2B). CD49b and CD73 were also 
both expressed on a subset of peripheral B cells, while peripheral B cells 
did not express CD112, CD325, and CD276, and all B cells were 
positive for CD53 (Fig. 2C). On the basis of these data, CD49b and 
CD73 represented potential surface markers for the identification 
of proangiogenic B cells.
CD73+CD49b+ B cells form a distinct population among 
circulating B cells
Staining of CD49b and CD73 on peripheral B cells from healthy 
individuals revealed a distinct CD73+CD49b+ population (Fig. 3A). 
Real-time quantitative PCR (qPCR) mRNA expression analysis of 
proangiogenic cytokines by B cell populations sorted based on sur-
face expression of CD49b and CD73 showed that the expression of 
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Fig. 1. A subset of B cells promotes angiogenesis. (A) Heat map showing gene-scaled (z score) log2 normalized counts of genes encoding secreted immunomodulatory 
proteins that are differentially expressed between proangiogenic B and nonangiogenic B cell clones (FDR < 0.01, log2 fold change > 0.5). The top box indicates genes with 
known proangiogenic effects, the middle box indicates genes with unknown or pleiotropic effects on angiogenesis, and the bottom box indicates genes with known 
anti-angiogenic effects. (B and C) Reads per kilobase million (RPKM) expression values from normal goat serum data (top) and real-time qPCR gene expression after prolonged 
(>3 weeks) in vitro expansion (bottom) of proangiogenic (n = 5) and nonangiogenic (n = 5) clones (mean ± SEM). *P < 0.05 and **P < 0.01, Mann-Whitney test. (B) Genes 
that were up-regulated in proangiogenic clones. (C) Genes that were down-regulated in proangiogenic clones. (D) Representative images of HUVEC tube formation assay to 
quantify proangiogenic effect of B cell clones (scale bars, 400 m). Negative control, IMDM +2% FCS; positive control, EGM medium with growth factors. (E) Quantitative 
analysis of rate of HUVEC tube formation induced by supernatants of pro- and nonangiogenic B cell clones (mean ± SEM). *P < 0.05 and **P < 0.01, Mann-Whitney test.
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TGFB2, MDK, FGF2, CYR61, and VEGFA was up-regulated in 
CD73+CD49b+ B cells compared to CD73−CD49b− B cells (Fig. 3B). 
Surface expression of CD39 as well as the VEGF receptor FLT1 was 
higher on CD73+CD49b+ B cells (Fig. 3C). The frequency of CD49b+ 
B cells was significantly increased after 3 days of in vitro stimulation 
of total B cells with CD40L + IL-21, whereas B cell stimulation with 
CD40L + IL-21 led to a reduction of CD73+ B cells (Fig. 3D).
Proangiogenic B cells show increased frequencies 
in circulation and are present in esophageal tissue 
of patients with EoE
To demonstrate an in vivo relevant function for proangiogenic 
B cells, we first investigated tissue biopsies and peripheral blood of 
patients with EoE. We observed a 3.2-fold increase in the median 
frequency of circulating CD73+CD49b+ B cells in patients with EoE 
compared to healthy controls (Fig. 4A). Furthermore, there was a 
moderate positive correlation between the frequency of circulating 
CD73+CD49b+ B cells and the number of eosinophils in lamina 
propria and stromal tissue of esophagus in patients with EoE 
(Fig. 4B). Moreover, transcriptional activity of several proangiogenic 
cytokine genes was significantly up-regulated in EoE esophageal 
biopsies compared to control esophageal biopsies. These included 
VGF, PDGFA, CYR61, FGF2, and MDK, while TGFB2, VEGFA, and 
ADM showed a trend toward higher expression (Fig. 4C). A sub-
group of five patients with EoE showed much higher up-regulation of 
these cytokines. No correlation was found between the proangiogenic 
cytokine expression levels and the frequency of circulating CD73+ 
CD49b+ B cells or the number of eosinophils in esophageal tissue 
of patients with EoE. Purified CD73+CD49b+ B cells isolated from 
peripheral blood of patients with EoE showed higher transcriptional 
levels of VEGFA, TGFB2, AMD, and FGF2 than CD73−CD49b− 
cells (Fig. 4D). Confocal microscopy staining of esophageal bio psies 
demonstrated that CD20+ B cells and/or CD138+ plasma cells 
were present in 50% (9 of 18) of EoE esophageal biopsies (Fig. 4E). 
VEGF-A+ B cells were detected in four of nine biopsies that con-
tained B cells (Fig. 4, F and H). In seven of these nine tissues 
(78%), IgG4+ B cells or plasma cells were detected. Some of 
these B cells expressed CYR61, as well as CD49b and CD73 
(Fig. 4, G and H).
Proangiogenic B cells show increased frequencies 
in circulation and are present in tumor tissue of patients 
with melanoma
Because angiogenesis is essential in tumor growth, we assessed the 
potential expression of proangiogenic B cells in the clearly defined, 
easily accessible, and relatively common tumor melanoma. First, we 
assessed the frequency of proangiogenic B cells in peripheral blood 
of patients with advanced metastatic melanoma. There was a sig-
nificantly increased frequency of CD73+CD49b+ B cells in the cir-
culation of these patients compared to healthy controls (Fig. 5A). 
Single-cell suspensions were prepared from surgically excised 
metastatic melanoma lesions from three patients with melanoma, 
and the expression of CD73 and CD49 was analyzed using flow 
cytometry. The frequencies of CD73+CD49b+ B cells were generally 
lower among tumor-infiltrating B cells compared to circulating 
B cells (Fig. 5B). This may indicate loss of surface markers due to 
enzymatic treatment required for cell isolation from tissue samples 
or down-regulation of CD49b upon migration into the tissue. Alter-
natively, CD73+CD49b+ cells may be induced by the tumor micro-
environment to migrate and accumulate in the blood.
The expression level of CD39 was significantly up-regulated 
on melanoma tumor-infiltrating CD73+CD49+ B cells compared to 
peripheral CD73+CD49b+ B cells from healthy controls as well as 
patients with melanoma (Fig. 5C). Coculture of B cells with the 
melanoma cell line FM55 alone did not significantly alter the ex-
pression of CD49b or CD73, while BCR stimulation down-regulated 
CD49b expression induced by IL-21 and CD40L in the presence or 
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Fig. 2. Proangiogenic B cells are characterized by expression of CD49b and CD73. (A) Heat map showing gene-scaled (z score) log2 normalized counts of CD marker– 
encoding genes that are differentially expressed between proangiogenic B and nonangiogenic B cell clones (FDR < 0.01, log2 fold change > 0.5). (B) Flow cytometry 
analysis of CD73 and CD49b surface expression on proangiogenic (black line) (n = 5) and nonangiogenic (red line) B cell clones (n = 20) (mean ± SEM). Grey dotted line 
indicates isotype control. *P < 0.05 and **P < 0.01, Mann-Whitney test. (C) Flow cytometry analysis of surface expression of CD73 and CD49b on freshly isolated peripheral 
blood B cells.
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Tumor-infiltrating B cells were detected in the vicinity of CD31+ 
blood vessels in eight of the nine analyzed tumor tissues at varying 
frequencies (Fig. 5D). VEGF-A+ and CD73+ B cells were detected 
in 75% (six of eight) of the tumor sections (Fig. 5, E and G). However, 
we could observe VEGF-A+CD73+ double-positive B cells only in 
three of these six (50%) tissues (Fig. 5, E and G). CD49b+ B cells 
were detected in 50% of the tissues that contained infiltrating B cells. 
All samples that contained CD49b+ cells also contained CD49b+ 
CD73+ B cells (Fig. 5, E to G). IgG4+ B cells were detected in all of 
the tumor tissues that contained B cells (eight of nine) (Fig. 5, 
F and G). Of the tissues that stained positive for IgG4+ B cells, 
62.5% contained IgG4+CD73+ B cells and 37.5% of the tissues that 
stained positive for IgG4+ B cells contained IgG4+CD73+ CD49b+ 
B cells (Fig. 5G).
DISCUSSION
An increasing number of studies demonstrate immunoregulatory 
or immune effector functions of B cells that extend beyond antibody 
production. Here, we report a population of human B cells that is 
capable of producing a wide range of proangiogenic cytokines and 
inducing angiogenesis.
A major limitation to detailed analysis of human B cells is their 
limited capacity to be cultured in vitro. This limitation can be largely 
overcome through transduction of B cells with BCL6 and BCL-XL, 
resulting in the formation of immortalized B cells that can be ex-
panded in vitro in the presence of IL-21 and CD40L for extended 
periods of time (23, 27). This method enables the generation and 
functional characterization of B cell clones. Transcriptomics analysis 
of IgG1- and IgG4-switched memory B cell clones revealed a distinct 
clustering based on the expression of cytokine genes. A cluster of 
IgG4+ B cell clones expressed a wide range of proangiogenic cyto-
kines including VEGFA, PDGFA, TGFB2, CYR61, BMP2, SLIT2, 
ADM2, FGF2, NOV, SPP1, PDGFC, NAMPT, HDGFRP3, CCL3, 
TNFRSF11B, IL8, and MDK. Functional experiments demonstrated 
that these clones were able to promote in vitro angiogenesis.
Differential expression analysis between pro- and nonangiogenic 
B cell clones identified CD49b and CD73 coexpression as a potential 
surface marker combination to characterize circulating B cells with 
a proangiogenic function. CD49b (also known as 21 integrin) is 
an integrin alpha subunit that is expressed on many cell types in-
cluding NK T cells, NK cells, fibroblasts, and platelets. CD49b, when 
coexpressed together with LAG-3, has also been identified as a marker 
for identification of Tr1 cells (13).
Extracellular adenosine can be generated by the ectonucleotidases 
CD73 and CD39. CD39 is ubiquitously expressed by B cells, whereas 
CD73 is expressed on a subset of human B cells, both in the peripheral 
blood and in the germinal centers (28, 29). We found that CD73+ 
B cells, independent of the expression of CD49b, expressed higher levels 
of CD39 than CD73− B cells. Although CD39 was not up- regulated 
on proangiogenic B cell clones, we observed a significantly higher 
expression level of CD39 in tumor-infiltrating CD73+CD49b+ B cells 
in patients with melanoma compared to peripheral CD73+ CD49b+ 
B cells. This suggests that tumor-infiltrating CD73+CD49b+ B cells 
have an increased capacity to convert ATP to adenosine as it has been 
reported that CD39hi B cells produce elevated levels of adenosine (30). 
Under normal physiological conditions, the levels of extracellular 
ATP are very low because it is localized in the cytosol. However, 
extracellular ATP levels can increase significantly in certain conditions 
such as inflammation, hypoxia, and malignancy (12). This ATP can 
be converted to free adenosine by cells that coexpress CD73 and CD39. 
Free adenosine can bind to A2a and A2b receptors and thereby pro-
mote angiogenesis and fibrosis and enhance suppressive function 
of Tregs, Tr1 cells, and myeloid-derived suppressor cells (12, 31). 
Therefore, strategies targeting CD39 and CD73 are currently being 
investigated as potential therapeutic interventions to restore antitumor 
immunity (12).
Recent findings have revealed that certain B cells may promote 
tumor progression. Different mechanisms seem to be involved in 
this process. B cell–deficient mice have been reported to mount 
strong cytotoxic antitumor responses against D5 mouse melanoma 
cells and MCA304 sarcoma cells, while wild-type mice failed to control 
tumor growth (32). The proposed responsible mechanism was that 
B cell–derived IL-10 could suppress interferon- production by CD8+ 
T cells and NK cells. Breg cells producing IL-10, IL-35, and TGF- 
have also been suggested to promote tumor progression though the 
suppression of T cell responses (1). A particular subset of plasma 
cells expressing IgA, IL-10, and PD-L1 has been shown to interfere 
with T cell–dependent immunogenic chemotherapy (33).
Angiogenesis plays a key role in physiological processes such as 
























































































































































































Fig. 3. CD49b+CD73+ B cells form a distinct population of B cells and express 
proangiogenic cytokines. (A) Gating of CD49b+CD73+ B cells in PBMCs of healthy 
donor. (B) mRNA expression of proangiogenic cytokines in B cell populations 
sorted based on their expression of CD49b and CD73 (n = 4). (C) Flow cytometric 
analysis of CD39 and FLT1 expression on CD49b+CD73+ B cells stained directly 
ex vivo. (D) Effect of 3-day in vitro stimulation of primary B cells on the expression 
of CD49b and CD73 (n = 4).
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Fig. 4. Proangiogenic B cell frequency is elevated in patients with EoE and correlates with esophageal eosinophil counts. (A) Frequencies of circulating 
CD73+CD49b+, CD73−CD49b−, CD73−CD49b+, and CD73+CD49b− B cells in patients with EoE (n = 12) compared to healthy controls (n = 10). Dot plots show representative 
stainings of CD49b and CD73 among CD19+ live cells from healthy controls or patients with EoE. (B) Correlation of circulating CD73+CD49b+ B cell frequencies and 
stroma/lamina propria eosinophil count. HPF, high-power field. (C) mRNA expression of proangiogenic cytokines in esophageal biopsies of patients with EoE (n = 18). 
(D) mRNA expression of proangiogenic cytokines in purified peripheral CD73−CD49b− and CD73+CD49b+ B cells from patients with EoE (n = 4). (E) Confocal microscopy 
staining for CD20 and CD138 on an esophageal biopsy from a patient with EoE. (F) Confocal microscopy staining of CD20, CD49b, CD73, CD138, and VEGF on EoE 
esophageal biopsy. (G) Confocal microscopy staining of CD20, CD49b, CD73, IgG4, and CYR61 on EoE esophageal biopsy. (H) Frequencies of tissues stained positive for 
B cells expressing different markers. The percentage of tissues in which CD20+ or CD138+ cells expressing indicated markers were detected is shown (n = 9).
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critical role in tumor metastasis and tissue remodeling in chronic 
inflammatory conditions such as EoE (6). We found an increased 
frequency of peripheral CD49b+CD73+ B cells in patients with 
melanoma and EoE. The frequencies of these cells in single-cell 
suspensions derived from melanoma tumor tissues were lower 
than in circulation. It remains unclear whether the detection of 
these cells is affected by the enzymatic treatment applied during 
the preparation of tissues or that the expression of particularly 
CD49b is down-regulated in the tumor microenvironment and 
under chronic inflammation in EoE.
There is increasing evidence that B cells can have a multitude 
of roles in regulating the tumor microenvironment and can have 
both pro- and antitumor effects (34). B cells can have a tumoricidal 
function primarily through the production of tumor antigen–specific 
immunoglobulins. In addition, B cells can act as antigen-presenting 
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Fig. 5. Proangiogenic B cells in patients with melanoma. (A) Frequency of circulating CD73+CD49b+ B cells in patients with melanoma (n = 19) compared to healthy 
controls (n = 20). (B) Frequency of CD73+CD49b+ B cells in matched PBMC and tumor-derived single-cell suspensions. (C) Expression level of CD39 on CD73−CD49b− and 
CD73+CD49b+ B cells from PBMCs and tumor tissue. (D) Confocal microscopy staining for CD20, CD138, and Melan A on melanoma tumor tissue. (E) Confocal microscopy 
staining of CD20, CD49b, CD73, IgG4, and VEGFA on melanoma tumor tissue. Arrows indicate CD138+ plasma cells positive for CD49b, CD73, and VEGFA. (F) Confocal 
microscopy staining of CD20, CD49b, CD73, IgG4, and CYR61 on melanoma tumor tissue. White arrows indicate CD20+ B cells positive for CD49b, CD73, and IgG4. Yellow 
arrows indicate CD20+ B cells stained positive for IgG4 and CYR61. (G) Frequencies of tissues stained positive for B cells expressing different markers. The percentage of 
tissues in which CD20+ or CD138+ cells expressing indicated markers were detected is shown (n = 8).
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T cells (34). The fact that the proangiogenic cytokine–producing 
B cell clones were IgG4-switched reinforces the previously reported 
connection between IgG4 production and tumor-promoting capacity 
(21). Tumor antigen–reactive IgG4 antibody production and IgG4 
irrespective of its tumor specificity were both found to impair the 
tumoricidal capacity of IgG1 antibodies specific for the melanoma- 
associated antigen, CSPG4 (chondroitin sulfate proteoglycan 4). 
Moreover, IgG4+ B cells were significantly increased in melanoma 
lesions compared to healthy skin, and serum IgG4 levels were inversely 
correlated with patient survival (21, 22). In addition to the findings 
in melanoma, IgG4 antibodies specific to culprit food proteins were 
found at high titers in adult and pediatric patients with EoE (18, 35). 
Granular deposits of IgG4 antibodies and IgG4+ plasma cells were 
detected in the lamina propria of patients with EoE (18). Patients 
with EoE also demonstrate clear signs of tissue remodeling in the 
esophagus including increased fibrosis, vascularity, and vascular 
activation (20, 36).
We have previously reported that IL-10–producing naive B cells 
are more prone to switch to IgG4-producing plasma cells than B cells 
that do not produce IL-10 (37). These cells were enriched among 
CD73−CD25+CD71+ B cells. Here, we report the identification of 
a B cell population that is characterized by the expression of IgG4, 
CD73, and CD49b; is capable of producing many proangiogenic 
cytokines; and exerts a proangiogenic function but does not produce 
IL-10. The expression of CD73 in these two IgG4-associated B cell 
populations is also linked to these functions. Namely, the CD73− 
fraction includes immune regulatory B cells, whereas CD73+ fraction 
includes proangiogenic B cells. As observed in the present study, 
multiple functions of memory B cells are reflected in different clusters 
of IgG4 memory B cells, indicating that not all of the cells that switch 
to IgG4 develop a proangiogenic phenotype. It would be interesting 
to further investigate the factors that differentiate these types of 
IgG4-switched B cells in further studies. IgG4+CD73+CD49b+ B cell 
clones produced a wide range of proangiogenic factors and facili-
tated endothelial tube formation. Elevated frequencies of CD73+ 
CD49b+ B cells were detected in patients suffering from melanoma 
and EoE, two model diseases with a demonstrated link to IgG4 
and angiogenesis. Together, our findings demonstrate a previously 
unidentified proangiogenic B cell subset characterized by the ex-
pression of CD49b and CD73.
MATERIALS AND METHODS
Generation and characterization of B cell clones
For the generation of B cell clones, peripheral blood mononuclear 
cells (PBMCs) from bee venom–exposed healthy or allergic individuals 
were isolated. Switched IgG+ (gated as CD19+IgM−IgA−) memory 
B cells were sorted using a FACSAria III (BD Biosciences, Franklin 
Lakes, NJ, USA) (fig. S1A). Cells were cocultured for 36 hours in 
IMDM (Iscove’s Modified Dulbecco’s Medium) (Gibco) [supple-
mented with 8% fetal calf serum (FCS) and penicillin/streptomycin] 
with -irradiated (50 gray) mouse L cell fibroblasts stably express-
ing CD40L (CD40L-L cells, 105 cells ml−1) cells and recombinant IL-21 
(Miltenyi Biotec) and immortalized using a retroviral vector contain-
ing BCL6, BCL-XL, and GFP as described previously (23). Single 
memory B cells were sorted and expanded with CD40L and IL-21. 
With this approach, we obtained 17 IgG1 clones, 10 IgG4 clones, 
3 IgG3 clones, and 2 IgG2 clones. We continued with focusing 
on IgG4 and IgG1 clones because we had significant numbers from 
these two subgroups. We were primarily interested in IgG4 clones 
that specifically clustered based on angiogenesis genes. To demon-
strate their clonality, RNA was isolated from individual expanded B 
cell clones (100,000 cells per clone). RNA was isolated using RNeasy 
Plus Micro Kit (Qiagen, Hilden, Germany). BCR sequence analysis 
was performed as described elsewhere (38).
RNA sequencing and data analysis
B cell clones were stimulated with goat anti-human IgG + IgM 
(H + L) F(ab′) fragment (10 g/ml; BCR stimulation) (Jackson 
ImmunoResearch, Cambridgeshire, UK) for 4 hours. Live GFP+ 
B cells were sorted using a FACSAria III (BD Biosciences, Franklin 
Lakes, NJ, USA). RNA was isolated using the RNeasy Plus Micro Kit 
(Qiagen, Hilden, Germany).
Total RNA samples (1 g) were ribosome-depleted and then 
reverse-transcribed into double-stranded cDNA, with actinomycin 
added during first-strand synthesis. cDNA samples were fragmented, 
end-repaired, and polyadenylated before ligation with TruSeq adapters. 
The adapters contain the index for multiplexing. Fragments con-
taining TruSeq adapters on both ends were selectively enriched by 
means of PCR. The quality and quantity of the enriched libraries 
were validated with a Qubit (1.0) Fluorometer and Bioanalyzer 2100 
(Agilent). The product was a smear with an average fragment size of 
approximately 360 base pairs (bp). The libraries were normalized to 
10 nM in 10 mM tris-Cl (pH 8.5) with 0.1% Tween 20.
A TruSeq SR Cluster Kit v4-cBot-HS or a TruSeq PE Cluster Kit 
v4-cBot-HS (Illumina) was used for cluster generation by using 8 pM 
of pooled normalized libraries on the cBOT. Sequencing was per-
formed on an Illumina HiSeq 2500 single-end 126-bp device by 
using TruSeq SBS Kit v4-HS (Illumina). Raw data are available at 
the Gene Expression Omnibus (GEO; accession no. GSE110278).
After quality control of raw reads with FastQC (version 0.10.0; 
Babraham Institute, Cambridge, UK), whole transcriptome quanti-
fication was performed using RSEM (version 1.2.18) (39) using the 
Ensembl version 75 annotations of the GRCh37.p13 human genome 
assembly. Differential expression analysis between conditions was 
performed using edgeR likelihood ratio test method (version 3.14.0) 
(40) on Trimmed Mean of M values (TMM) normalized counts. The 
Benjamini-Hochberg procedure (41) was used to adjust p values 
and genes with an FDR < 0.01 and a log2 fold change > 0.5 were 
considered differentially expressed. For clustering, TMM normalized 
counts were log2-transformed and converted to row scaled z scores 
(41). Then, a distance matrix was calculated using Euclidean distance 
and hierarchical clustering was performed using the “complete 
linkage” clustering algorithm. Cluster analysis did not reveal a clus-
tering that was biased on the basis of donor type or antigen specificity 
(fig. S2 and table S1). The set of CD (cluster of differentiation) 
markers was obtained from UniProt (www.uniprot.org/docs/cdlist.
txt) (42), and the set of genes encoding secreted immunomodulatory 
proteins (including cytokines and chemokines) was obtained from 
the Immunology Database and Analysis Portal (ImmPort) (www.
immport.org/immport-open/public/reference/genelists) (43). Heat 
map plots were generated with the ComplexHeatmap R/bioconductor 
package (44). The GEO accession number for the global gene tran-
scriptional analysis reported here is GSE129616.
Patient selection and sample collection
Peripheral blood samples were obtained from patients with EoE, mela-
noma, and healthy controls. PBMCs were isolated and cryopreserved. 
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Peripheral blood and tissue samples from patients with melanoma 
were obtained from the University of Zürich and the Cantonal 
Hospital St. Gallen Biobanks. EoE patient samples were from the 
Swiss Eosinophilic Esophagitis Cohort Study. Recruitment of pa-
tients, documentation of informed consent, collection of blood and 
tissue specimens, and experimental measurements were carried 
out with ethical approval from the Ethikkommission Ostschweiz 
(EKOS 16/079), the Ethikkommission Zürich (EK no. 647), and the 
Ethikkommission Nordwest- und Zentralschweiz (EKNZ 2015-388). 
Single-cell suspensions from resected tumor tissue from patients 
with melanoma were obtained using a tumor dissociation kit, human 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Patient character-
istics are listed in table S2 (melanoma) and table S3 (EoE).
Tube formation assay
HUVECs (Angioproteomie, Boston, MA, USA) were seeded at a 
density of 5000 cells/cm2 on a culture flask coated with Speed 
Coating Solution (PeloBiotech, Planegg, Germany) and grown until 
confluence in Endothelial Cell Growth Medium, EGM-2 (Lonza, 
Basel, Switzerland) containing 2% FCS (Sigma-Aldrich) and growth 
supplements. HUVECs were trypsinized and resuspended in B cell 
culture supernatants obtained from B cell clones that were stimu-
lated and cultured for 3 days in IMDM in the presence of CD40L + 
IL-21 (25 ng/ml) and anti-BCR (10 g/ml; Jackson ImmunoResearch 
Europe, Newmarket Suffolk, UK). As positive control, HUVECs 
were cultured on the matrigel in EGM-2 medium, and as negative 
control, cells were cultured in IMDM (Gibco) supplemented with 
2% FCS and penicillin/streptomycin. HUVECs were plated at a 
density of 2 × 104 per well in triplicates in a 48-well plate coated 
with 100 l of Matrigel Growth Factor Reduced Basement Membrane 
Matrix (Corning, Wiesbaden, Germany) and incubated for 22 hours 
at 37°C in an atmosphere containing 5% CO2. After incubation, 
medium was removed and plates were washed with PBS. Formation 
of capillary-like structures was observed using an LSM 510 META 
confocal laser-scanning inverted microscope (Zeiss, Oberkochen, 
Germany). Phase-contrast images of a representative area were 
taken at ×10 magnification and processed with Photoshop CC 2017 
(Adobe Systems). Tube formation was quantified using ImageJ 
1.51h (Wayne Rasband, National Institute of Health, USA) and 
Angiogenesis Analyzer plugin (Gilles Carpentier, Universite Paris 
Est Creteil Val de Marne, France). The method for quantification 
of tube-like structures is illustrated in fig. S4.
Flow cytometry
Immunophenotyping was performed on PBMCs from patients and 
healthy individuals. The antibodies used for staining are listed in 
table S4. Zombie yellow (BioLegend, San Diego, CA) was used for 
dead cell exclusion. Samples were measured by multicolor flow 
cytometry (FACSAria III, BD Biosciences, Franklin Lakes, NJ, USA). 
Data were analyzed using FlowJo v10.0.7 (Tree Star, Ashland, OR).
Bead suspension array
Immunoglobulin heavy-chain isotypes of B cell clones were de-
termined by analysis of cell culture supernatants of B cell clones 
using the Bio-Rad Bio-Plex Pro Human Isotyping Assay (Bio-Rad, 
Hercules, CA).
Real-time qPCR
EoE tissue biopsies were stored in RNAlater RNA stabilization 
reagent (Qiagen, Hilden, Germany) and stored at −80°C. RNA was 
isolated from EoE esophageal biopsies using a Precellys 24 tissue 
homogenizer according to the manufacturer’s instructions (Bertin 
Technologies SAS, Montigny-le-Bretonneux, France). RNA from 
B cells was isolated using the RNeasy Plus Micro Kit (Qiagen, Hilden, 
Germany). mRNA was reverse-transcribed with the Revert Aid RT 
Kit (Thermo Fisher Scientific, Waltham, MA USA). Real-time 
qPCR was performed on a 7900HT Fast Real-Time PCR system 
(Thermo Fisher Scientific, Waltham, MA, USA) using the Maxima 
Sybr Green/Rox qPCR Master Mix (Thermo Fisher Scientific, 
Waltham, MA, USA) protocol. The primers used are listed in table S5. 
Results were normalized to EF1a (eukaryotic translation elongation 
factor 1 alpha) expression for each sample. Gene expression levels, 
shown in arbitrary units, were calculated by subtracting EF1a cycle 
threshold (Ct) from the gene Ct to obtain the Ct value. Arbitrary 
units for each sample = 10,000 × (2−Ct).
Confocal microscopy
Paraffin-embedded melanoma sections underwent deparaffinization 
and rehydration (2 × 10 min in xylol, 2 × 3 min in 100% isopropanol, 
2 × 3 min in 96% isopropanol, 3 min in 70% isopropanol, and 2 × 
5 min in H2O), followed by antigen retrieval by boiling the sections 
in sodium citrate buffer [10 mM sodium citrate and 0.05% Tween 
20 (Sigma-Aldrich) in PBS (pH 6)] in a pressure cooker for 4 min. 
The frozen EoE samples were cut with a microtome (Leica 
CM3050S) with a thickness of 7 m and stored at −80°C until use. 
Before staining, sections were defrosted and dried by air and fixated 
with 4% paraformaldehyde for 10 min and washed three times with 
PBS for 5 min.
For both frozen and paraffin sections, nonspecific binding 
was blocked by incubating for 25 min with Perm/blocking buffer 
(1% BSA, 0.2% Triton X-100, and 10% goat serum in PBS). Then, 
sections were sequentially stained with the following combinations 
of antibodies: (I) CYR61 (followed by secondary staining with goat 
anti-mouse IgG-AF405), CD20 (followed by secondary staining with 
goat anti-rabbit IgG-AF488), CD73 (followed by secondary staining 
with goat anti-mouse IgG2b-AF594), IgG4-Dylight650 and CD49b-
AF546, (II) CD138 (followed by secondary staining with goat anti- 
mouse IgG-AF405), CD20 (followed by secondary staining with goat 
anti-rabbit IgG-AF488, CD73 (followed by secondary staining with 
goat anti-mouse IgG2b-AF594), VEGF-A-Dylight633 and CD49b-
AF564, (III) matching isotype controls. Details regarding these anti-
bodies and dilutions can be found in table S6. All antibodies were 
incubated for 45 min at room temperature, and in between antibodies, 
they were washed three times for 5 min with PBS. After staining, sec-
tions were coverslipped with ProLong Diamond (Invitrogen, Carlsbad, 
CA, USA) and dried for 24 to 72 hours before images were taken. 
Images were acquired and analyzed with a ZEISS LSM780 confocal 
microscope and the software ZEN 2012.
Images were acquired with a Zeiss LSM 780 confocal microscope 
(Carl Zeiss, Oberkochen, Germany) in lambda mode with a 40× oil 
immersion objective with the lasers (405 to 488 nm). Full spectrum 
data range was used, and the used fluorophores were first added 
to the database as single staining; furthermore, autofluorescence of 
the different tissues was measured. After acquiring the images, 
linear unmixing was performed, with the fluorophores and the auto-
fluorescence. Then, histogram stretching was performed to enhance 
the quality of the pictures. PMT pictures were made at the same 
spot as pictures with the laser lines to provide an overview of the 
tissue. From each tissue, four images of areas containing CD20+ 
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B cells or CD138+ plasma cells were analyzed. In each tissue, the 
presence of IgG4+, VEGF+, Cyr61+, CD73+, VEGF+CD73+, CD49b+, 
and CD73+CD49b+ cells was determined. If cells expressing these 
markers were detected in a tissue, it was scored as positive. The per-
centage of positive tissues was calculated as the ratio between tissues 
positively stained for the markers and the total tissues analyzed.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/20/eaaz3559/DC1
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